Peer-reviewed articleOpen access

Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities.

Pharmacological reports : PRMar 11, 2026License: open accessUnited States1 citationsDOI: 10.1007/s43440-026-00843-9

Abstract

Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and urge careful consideration of risks and benefits when considering ketamine for individuals with TRD and SUDs.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepressionAddiction

Keywords

Transcranial magnetic stimulationSubstance Use DisordersElectroconvulsive TherapyTreatment-resistant Depression

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.

Chiappini S, d'Andrea G, De Filippis S +10

Europe PMC2023

ArticleMDMA

Prevalence and Psychiatric Correlates of Illicit Substance Use in UK Undergraduate Students.

Foster H, Stevenson J, Akram U

Europe PMC2023